The European Medicines Agency said on Tuesday it is still unclear whether the existing COVID-19 vaccines will need to be modified in order to be effective against the Omicron coronavirus variant.
"There is no answer whether we will need to adapt vaccines," the EMA's Executive Director Emer Cook told reporters, noting the European Union is now able to produce 300 million vaccine doses per month to meet the rising demand.
The EU yesterday added another vaccine to its roster of existing means in the battle against COVID-19, with Novavax's jab Nuvaxovid receiving the nod from the EMA and the European Commission.
